SCHEMBL1136367

SCHEMBL1136367

C=C(C)OC(=O)CCCC

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
CES1 P23141 2/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CES2 O00748 1/20 0.44
DGKA P23743 1/20 0.43
TSHR P16473 3/20 0.41
TP53 P04637 1/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40
PAM P19021 2/20 0.39
CA1 P00915 1/20 0.39
NAAA Q02083 1/20 0.39
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1417444 0.93 DGKA (0.52) ALDH1A1CES1HSD17B10TDP1CES2
SCHEMBL10804075 0.91 DGKA (0.55) ALDH1A1CES1HSD17B10TDP1CES2
SCHEMBL6430114 0.91 DGKA (0.55) ALDH1A1CES1HSD17B10TDP1CES2
SCHEMBL19532024 0.91 DGKA (0.55) ALDH1A1CES1HSD17B10TDP1CES2
SCHEMBL11155522 0.91 DGKA (0.55) ALDH1A1CES1HSD17B10TDP1CES2
SCHEMBL10454969 0.91 DGKA (0.55) ALDH1A1CES1HSD17B10TDP1CES2
SCHEMBL1417378 0.91 DGKA (0.55) ALDH1A1CES1HSD17B10TDP1CES2
SCHEMBL11122471 0.91 DGKA (0.55) ALDH1A1CES1HSD17B10TDP1CES2
SCHEMBL2351728 0.91 DGKA (0.55) ALDH1A1CES1HSD17B10TDP1CES2
SCHEMBL1417334 0.91 DGKA (0.55) ALDH1A1CES1HSD17B10TDP1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497374-B2 Processes and intermediates for the preparations of benzoprostacyclin analogues and benzoprostacyclin analogues prepared therefrom CHIROGATE INTERNATIONAL INC. (TW) 2025-12-16 US claimed
US-12221411-B2 Processes and intermediates for the preparation of carbaprostacyclin analogues CHIROGATE INTERNATIONAL INC. (TW) 2025-02-11 US claimed
EP-4098651-B1 PROCESS FOR THE PREPARATION OF BERAPROST OR SIMILAR BENZOPROSTACYCLIN ANALOGUES STARTING FROM 2-(3-BROMO-2-FLUOROPHENYL)-4-HYDROXYCYCLOPENT-2-ENONE OR SIMILAR REACTANTS CHIROGATE INT INC (TW) 2024-02-07 EP claimed
US-20230416216-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF BENZOPROSTACYCLIN ANALOGUES AND BENZOPROSTACYCLIN ANALOGUES PREPARED THEREFROM CHIROGATE INTERNATIONAL INC. (TW) 2023-12-28 US claimed
US-20230357119-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES CHIROGATE INTERNATIONAL INC. (TW) 2023-11-09 US claimed
US-20230357118-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES CHIROGATE INTERNATIONAL INC. (TW) 2023-11-09 US claimed
CN-117003630-A Methods and intermediates for preparing carboprostacyclin analogs 佳和桂科技股份有限公司 2023-11-07 CN claimed
US-20230002339-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF BENZOPROSTACYCLIN ANALOGUES AND BENZOPROSTACYCLIN ANALOGUES PREPARED THEREFROM CHIROGATE INTERNATIONAL INC. (TW) 2023-01-05 US claimed
EP-4098651-A1 PROCESS FOR THE PREPARATION OF BERAPROST OR SIMILAR BENZOPROSTACYCLIN ANALOGUES STARTING FROM 2-(3-BROMO-2-FLUOROPHENYL)-4-HYDROXYCYCLOPENT-2-ENONE OR SIMILAR REACTANTS Chirogate International Inc. (TW) 2022-12-07 EP claimed
CN-115433071-A Methods and intermediates for preparing benzoprostacyclin analogs, and benzoprostacyclin analogs prepared therefrom 佳和桂科技股份有限公司 2022-12-06 CN claimed
EP-1811037-A1 Process for the preparation of optically active cyclopentenones Chirogate International Inc. (TW) 2007-07-25 EP claimed
US-20070166809-A1 Processes for the preparations of optically active cyclopentenones and cyclopentenones prepared therefrom CHIROGATE INTERNATIONAL INC. 2007-07-19 US claimed
EP-0560408-B1 Enantio- and regioselective syntheses of organic compounds using enol esters as irreversible transacylation reagents SEARLE & CO (US) 2000-04-05 EP claimed
EP-0454463-B1 Process for producing epoxyalcohols of high optical purity ARCO CHEM TECH (US) 1997-08-13 EP claimed
EP-0357009-B1 Method of resolution of hydroxy-cyclopentenones using a lipase and transacylation agents SEARLE & CO (US) 1994-03-02 EP claimed
US-5278070-A Process for producing epoxyalcohols of high optical purity ARCO CHEMICAL TECHNOLOGY, L.P. (US) 1994-01-11 US claimed
EP-0560408-A1 Enantio- and regioselective syntheses of organic compounds using enol esters as irreversible transacylation reagents G.D. SEARLE & CO. (US) 1993-09-15 EP claimed
US-5106750-A Enzymatic resolution of hydroxycyclopentenones using lipase G. D. SEARLE & CO. (US) 1992-04-21 US claimed
EP-0454463-A2 Process for producing epoxyalcohols of high optical purity ARCO Chemical Technology, L.P. (US) 1991-10-30 EP claimed
EP-0357009-A2 Method of resolution of hydroxy-cyclopentenones using a lipase and transacylation agents G.D. Searle & Co. (US) 1990-03-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357119-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES PTGIS, PTGIR, PTGES ALDH1A1 1718/4885CES1 557/4885HSD17B10 206/4885
US-20230357118-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES PTGIS, PTGIR, PTGES ALDH1A1 1718/4885CES1 557/4885HSD17B10 206/4885
US-12221411-B2 Processes and intermediates for the preparation of carbaprostacyclin analogues PTGIS, PTGIR, PTGES ALDH1A1 1718/4885CES1 557/4885HSD17B10 206/4885
US-20230416216-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF BENZOPROSTACYCLIN ANALOGUES AND BENZOPROSTACYCLIN ANALOGUES PREPARED THEREFROM PTGIS, PTGER1, PTGIR ALDH1A1 1266/4885CES1 118/4885HSD17B10 491/4885
US-12497374-B2 Processes and intermediates for the preparations of benzoprostacyclin analogues and benzoprostacyclin analogues prepared therefrom PTGIS, PTGER1, PTGIR ALDH1A1 1266/4885CES1 118/4885HSD17B10 491/4885
US-20230002339-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF BENZOPROSTACYCLIN ANALOGUES AND BENZOPROSTACYCLIN ANALOGUES PREPARED THEREFROM PTGIS, PTGIR, PTGES ALDH1A1 1759/4885CES1 405/4885HSD17B10 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.